Skip Navigation



Annals of Oncology Advance Access published online on January 12, 2009
Annals of Oncology, doi:10.1093/annonc/mdn658
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/475    most recent
mdn658v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Enzinger, P. C.
Right arrow Articles by Fuchs, C. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enzinger, P. C.
Right arrow Articles by Fuchs, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer

P. C. Enzinger1,*, D. P. Ryan2, J. W. Clark2, A. Muzikansky3, C. C. Earle1, M. H. Kulke1, J. A. Meyerhardt1, L. S. Blaszkowsky2, A. X. Zhu2, P. Fidias2, M. M. Vincitore1, R. J. Mayer1 and C. S. Fuchs1,4

1 Department of Medical Oncology, Dana-Farber Cancer Institute
2 Division of Hematology/Oncology and
3 Biostatistics Center, Massachusetts General Hospital
4 Channing Laboratory, Brigham and Women's Hospital, Boston, MA, USA

* Correspondence to: Dr P. C. Enzinger, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Tel: +1 (617) 632-6855; Fax: +1 (617) 632-5370; E-mail: peter_enzinger{at}dfci.harvard.edu

Background: Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer.

Patients and methods: We carried out a phase I dose-escalation study of weekly docetaxel, cisplatin, and irinotecan (TPC), given on days 1 and 8 every 3 weeks, in patients with chemonaive solid tumors. Subsequently, we completed a multiinstitutional phase II study of TPC in patients with previously untreated, metastatic esophagogastric cancer.

Results: Thirty-nine patients were enrolled in the phase I trial; a weekly schedule of TPC was well tolerated. On that basis, docetaxel 30 mg/m2, cisplatin 25 mg/m2, and irinotecan 65 mg/m2 were selected for the phase II trial, where in the first 18 patients irinotecan 65 mg/m2 caused too much diarrhea and was reduced to 50 mg/m2. Among 56 eligible patients with previously untreated, metastatic esophagogastric cancer enrolled in the phase II trial, three complete and 27 partial responses were observed (overall response rate = 54%), and 15 patients (30%) had stable disease. Median progression-free survival was 7.1 months, and median survival was 11.9 months. At the final irinotecan dose of 50 mg/m2, grade 3 or higher toxicity included diarrhea (26%), neutropenia (21%), nausea (18%), fatigue (16%), anorexia (13%), and thrombosis/embolism (13%).

Conclusions: Weekly TPC is an active and well-tolerated regimen for patients with esophagogastric cancer.

chemotherapy, cisplatin, docetaxel, esophageal cancer, gastric cancer, irinotecan

Received for publication June 5, 2008. Revision received August 4, 2008. Accepted for publication September 3, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.